We are advancing programs targeting BET bromodomains in oncology and other disorders with significant unmet medical need. Our lead product, ZEN-3694, a BET inhibitor, in combination with enzalutamide, is advancing in clinical trials for treatment of metastatic castration resistant prostate cancer in patients that have progressed on an androgen receptor antagonist.

Also, in collaboration with Pfizer, we are advancing ZEN-3694 in combination with talazoparib into a Phase 1b/2 study in triple negative breast cancer patients that do not have a BRCA1/2 mutation. This is expected to greatly expand the patient population currently addressed by PARP inhibitors.

Our development strategy is focused on targeting patient subsets with high unmet need and those that are most likely to benefit from therapy.  We have built a rich clinical translational program, guided by pre-clinical evidence and biological rationale to implement patient pre-selection strategies into clinical trial designs.